thalidomide has been researched along with phrenosin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jian, W; Lerner, SP; Levitt, JM; Sonpavde, G | 1 |
| Dolak, W; Kiesewetter, B; Kornauth, C; Lukas, J; Mayerhoefer, ME; Raderer, M; Simonitsch-Klupp, I | 1 |
2 other study(ies) available for thalidomide and phrenosin
| Article | Year |
|---|---|
The preclinical activity of lenalidomide in indolent urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cerebrosides; Drug Screening Assays, Antitumor; Female; Humans; Immunohistochemistry; Lenalidomide; Mice; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Pathologic; Thalidomide; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cerebrosides; Female; Humans; Immunohistochemistry; Lenalidomide; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Thalidomide; Treatment Outcome | 2018 |